Department of Brain Health News
The UNLV department of brain health advances research, education, and practice to improve the care and treatment of individuals with brain disorders. Our students receive guidance from faculty who specialize in a range of areas from basic and clinical research in neurodegenerative disease, neuropsychology, and occupational therapy.
Current Brain Health News
The 'Brain Health Frontiers: Tackling Alzheimer's Together' panel discussion highlighted the revolutionary research the Department of Brain Health is conducting to fight Alzheimer’s disease.
UNLV Brain Health researcher Lina Nih is developing a treatment that could one day alter how practitioners address stroke recovery.
An enduring UNLV end-of-semester tradition is to highlight exceptional students who embody the academic, research, and community impact of the graduating class.
The associate dean of research in Integrated Health Sciences leans into his own immigrant story to provide others with opportunities.
Entities sign Memorandum of Understanding to cultivate best-in-class clinical research services for Alzheimer’s and other neurodegenerative diseases.
First-of-its-kind database, supported by Alzheimer's Drug Discovery Foundation, will provide greater access to key data on Alzheimer’s to researchers around the world.
Brain Health In The News
Doctor Jeffrey Cummings is world-renowned in the field of Alzheimer’s research and he leads UNLV’s Center for Transformative Neuroscience. He and six other scientists published research Wednesday that looked at the potential existing drugs have for the research and treatment of Alzheimer’s, for example, drugs like rasagiline for Parkinson’s or bexarotene for cancer. It’s called repurposing.
Axsome’s expectation that AXS-05 can win market share from Rexulti is partly built on the belief that the drug candidate has a differentiated safety profile. Rexulti has a boxed warning because of an increased risk of death. There were no deaths in the AXS-05 trials. Jeffrey Cummings, a research professor at the University of Nevada, Las Vegas, discussed what may happen if AXS-05 avoids a boxed warning.
Axsome Therapeutics said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer’s disease, after it succeeded in three out of four late-stage studies.
Today, Axsome will host a conference call and webcast to discuss these topline results. Dr. Jeffrey Cummings, Vice Chair of Research at UNLV Department of Brain Health, will join the call and be available for questions.
Cleveland Clinic Genome Center researchers have unraveled how microglia, which perform key neuroprotective activities, also can transform and drive harmful processes such as inflammation in Alzheimer’s disease.
The Food and Drug Administration (FDA) has granted 510(k) clearance to Icobrain Aria (Icometrix, Boston, MA), a software that provides computer-assisted, automatic detection and severity grading for amyloid-related imaging abnormalities (ARIA). Icobrain Aria generates a quantitative summary report for MRI images, including severity rating scores based on the measurement and summarization of ARIA cerebral edema (ARIA-E) and ARIA cerebral microhemorrhages (ARIA-H) sites of involvement.
